Gastroenterology Licensing Deal Benchmarks 2026

Anti-TL1A Crohn's (Phase 2)

$3.3B

Total deal value

IL-23 UC (Phase 2)

$3.0B

Total deal value

mAb EoE (Phase 2)

$2.9B

Total deal value

GI Royalties

8.1%-15.1%

Base tier range

Model Your Deal

Market Analysis

Gastroenterology has emerged as one of the most dynamic licensing areas in biopharma, fueled by the validation of novel targets like TL1A and the continued expansion of IL-23 and integrin pathways. The Merck/Prometheus Biosciences acquisition at $10.8B for anti-TL1A set a transformative valuation benchmark for the GI space. Phase 2 anti-TL1A deals for Crohn's disease carry a median total deal value of $3.3B, while IL-23 approaches to UC reach $3.0B.

GI deal structures reflect the chronic nature of IBD treatment (lifelong therapy), large patient populations (3M+ US IBD patients), and well-defined clinical endpoints (endoscopic remission, clinical remission). The growing focus on combination approaches (IL-23 + TL1A, biologics + JAK inhibitors) is driving platform deal interest. EoE deals average $2.9B as dupixent validated the eosinophilic pathway.

Royalty rates across GI licensing range from 8.1% to 15.1% at the base tier. Key valuation drivers include differentiation versus adalimumab and vedolizumab, oral versus injectable formulation, mucosal healing rates, and potential for steroid-free remission. The biosimilar erosion of adalimumab (Humira) has created opportunity for next-generation targeted therapies with superior efficacy profiles.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are the highest-value GI deal modalities in 2026?

Anti-TL1A antibodies lead in deal value at $3.3B for Phase 2 Crohn's programs, validated by the $10.8B Merck/Prometheus acquisition. IL-23 inhibitors for UC reach $3.0B, while gut-selective approaches with improved safety profiles are attracting growing interest.

How do GI deal terms compare to other immunology TAs?

GI deal terms are increasingly competitive with broader immunology (rheumatology, dermatology) due to large chronic patient populations and growing standard-of-care gaps. The validated clinical endpoints (endoscopic remission) and chronic treatment model support strong deal economics.

Which GI indications are most actively licensed?

Crohn's disease and ulcerative colitis dominate deal volume, followed by EoE, celiac disease, and IBS. Emerging indications like pouchitis and short bowel syndrome offer niche opportunities with limited competition and orphan-like commercial profiles.

What trends are shaping GI licensing in 2026?

Key trends include the TL1A pathway validation driving a wave of follow-on licensing, oral integrin modulators competing with injectable therapies, combination biologic approaches for refractory IBD, precision medicine strategies based on gut microbiome profiling, and expansion into eosinophilic GI disorders.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Gastroenterology Licensing Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Anti-TL1A Deal Benchmarks

IL-23 GI Deal Benchmarks

Phase 2 Deal Benchmarks

Small Molecule Deals

Ready to Calculate Your Deal Terms?